Skip to main content
Premium Trial:

Request an Annual Quote

Strata Oncology Strata Select

Strata Oncology has launched a new test called Strata Select, which employs what the firm calls the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit described earlier this year in a publication in Communications Medicine.

The Immunotherapy Response Score integrates tumor mutational burden, PD-L1 and PD-1 expression, and tumor microenvironment components. It is generated from Strata's larger tumor profiling services, which are covered by Medicare contractor Palmetto under the MolDX program.